ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FOCL / forecast
ELMD (63) HSDT (31) CV (43) VANI (28) ⌘ Pro Terminal →

EDAP TMS S.A. (FOCL) 12-Month Stock Forecast & Price Target Cone

$4.18 +0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.17

EDAP TMS S.A. (FOCL) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $192.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FOCL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FOCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, EDAP TMS S.A. (NASDAQ: FOCL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.18 (+0.24% 1D, market cap $192.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FOCL ranks #860 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FOCL compare to ELMD and HSDT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), FOCL carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 42.5%, and ROIC of -35.0%. By comparison, ELMD (Electromed Inc.) holds a C grade (63/100 RQD, P/E 30.4x, ROIC 24.1%, cap $224.1M) and HSDT (Solana Company (Class A)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $135.5M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while ELMD leads on capital efficiency (24.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FOCL?
▼

Per FOCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041934), EDAP TMS S.A. generated $70.5M in revenue (+1.6% YoY), -$29.2M in net income, and -$16.4M in free cash flow against $79.0M in total assets and $15.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.17 (-0.15%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (4)Whales (8)SEC (8)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.4% Base Target
$7 Bull$4 Base$3 Bear
📬 FREE FOCL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FOCL)Realized 20D OHLCV Swing Band: ±12.3%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY FOCL SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$4.20+0% Next Q
Q2 (-2Q)
33
Grade E$4.20-1.9% Next Q
Q3 (-1Q)
31
Grade E$4.12+1.5% Next Q
Current
28
Grade E$4.18-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FOCL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FOCL currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.25) and Max Pain ($4.39) forces dealer call-delta covering toward $6.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FOCL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FOCL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your FOCL Position Size: $10,000

Shares at $4.18: 2392.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $2.82
$6,746
$-3,254 (-32.5%)
12M Consensus BaseTarget $3.62
$8,660
$-1,340 (-13.4%)
12M Bull Case BreakoutTarget $6.72
$16,077
+$6,077 (+60.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$669%B
JP MorganUS Large-Cap ResearchSELL$358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FOCL)

  • ✓Walkthrough of FOCL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FOCL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.15%⚡ TESTING RESISTANCE
2026-11-03O $4.17H $4.18L $4.17C $4.18VOL 66.1K
RES: $4.37SUP: $3.96SMA50: $4.25SMA200: $4.41
$6.65$5.63$4.62$3.60$2.59RES $4.37SUP $3.96$4.182026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FOCL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FOCL Butterfly Map → + Track FOCL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +1.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FOCL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FOCL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FOCL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FOCL)

Health Care Rank #860 of 1015 ⚔️ ELMD vs FOCL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FOCL vs. ELMD, HSDT, CV, VANI)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, EDAP TMS S.A. (FOCL) ranks #860 by composite RQD confidence (28/100, grade E) and #578 by equity capitalization ($192.1M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while ELMD leads on capital efficiency and profitability with 24.1% ROIC and 78.1% gross margin. ELMD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with FOCL at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FOCL ACTIVE
EDAP TMS S.A.
E 28/100 — 42.5% -35.0% +0.24% $192.1M Benchmark Subject
ELMD
Electromed Inc.
C 63/100 30.4x 78.1% 24.1% -2.31% $224.1M /elmd-vs-focl →
HSDT
Solana Company (Class A)
E 31/100 — 96.0% -35.0% -7.52% $135.5M /hsdt-vs-focl →
CV
CapsoVision Inc.
D- 43/100 — 52.9% -35.0% -1.58% $363.3M /cv-vs-focl →
VANI
Vivani Medical Inc.
E 28/100 3.9x — -35.0% -4.39% $98.3M /vani-vs-focl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001041934 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), EDAP TMS S.A. (FOCL) reported GAAP revenue of $70.5M (+1.6% vs. FY2024 revenue of $69.4M ) , GAAP net income of -$29.2M, operating cash flow of -$16.4M, and free cash flow of -$16.4M (-11.6% YoY). On the balance sheet, FOCL closed FY2025 with $79.0M in total assets against $15.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $70.5M -$29.2M -$16.4M -$16.4M $79.0M $15.9M
FY2024 (FY) 2024-12-31 $69.4M -$20.6M -$14.7M -$14.7M $89.4M $2.2M

3. FOCL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FOCL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, EDAP TMS S.A. (NASDAQ: FOCL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.18 (+0.24% 1D, market cap $192.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FOCL ranks #860 in composite RQD confidence.

How does FOCL compare to ELMD and HSDT in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), FOCL carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 42.5%, and ROIC of -35.0%. By comparison, ELMD (Electromed Inc.) holds a C grade (63/100 RQD, P/E 30.4x, ROIC 24.1%, cap $224.1M) and HSDT (Solana Company (Class A)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $135.5M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while ELMD leads on capital efficiency (24.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FOCL?

Per FOCL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041934), EDAP TMS S.A. generated $70.5M in revenue (+1.6% YoY), -$29.2M in net income, and -$16.4M in free cash flow against $79.0M in total assets and $15.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FOCL trading relative to its 50-day, 200-day, and 52-week technical levels?

FOCL last traded at $4.18 (+0.24% on volume of 66,143 shares), positioning the stock -1.65% below its 50-day simple moving average ($4.25) and -5.22% below its 200-day simple moving average ($4.41). Across its 52-week range of $1.82 to $6.40, FOCL sits at the 51.5% percentile with a 14-day RSI of 47.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($3.67 to $4.69).

Direct Sub-Reports: FOCL RQD Cockpit FOCL 12M Forecast FOCL Earnings & Move FOCL Dividends & DRIP FOCL Insiders & 13F FOCL Whale Options FOCL Profit Sankey FOCL News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

FOCL — EDAP TMS S.A.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

EDAP TMS S.A. (FOCL) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.18 (+0.24% 1D, market capitalization $192.1M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 42.5%, operating margin of -35.0%, and free cash flow yield of -8.56%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of 0.82x.

2. Business Model, Unit Margins & SEC Financial Trajectory

EDAP TMS S.A. (FOCL) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. The company reported revenue of $70.5M for FY 2025. Market capitalization is $0.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), EDAP TMS S.A. (FOCL) reported $70.5M in annual revenue (up from $69.4M in FY2024, +1.6% YoY) and -$29.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($69.4M revenue, -$20.6M net income) through FY2025, FOCL scaled operating cash flow to -$16.4M and free cash flow to -$16.4M, backed by $79.0M in total assets against $15.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.56% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $1.82 – $6.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -35.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and bottlenecks are therefore — The company's sector and industry classification is listed as Health Care and Electromedical & Electrotherapeutic Apparatus, but the source does not map any supplier or customer relationships.

  • Key Question #1: Can FOCL sustain or expand its -35.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $70.5M and free cash flow of -$16.4M, how will capital allocation balance growth reinvestment against $15.9M in total debt?
  • Key Question #3: How sensitive is FOCL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FOCL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for EDAP TMS S.A. (FOCL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FOCL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FOCL Bull vs. Bear Conversation Board — What's Your Call at $4.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FOCL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FOCL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $5.14 (+23.0%)
📌 Pinned Debate

Revenue held roughly flat, rising from $69.4M to $70.5M, while the stock trades near the low end of its $1.82 - $6.4 52-week range.

The street is overcomplicating EDAP TMS S.A. (FOCL). Revenue held roughly flat, rising from $69.4M to $70.5M, while the stock trades near the low end of its $1.82 - $6.4 52-week range.. With an RQD score of 28/100 (E) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $4.51.

EarningsSniper 🐂 BULL

@FadeTheHype Shorting a 8/20 institutional whale-flow stock at $4.18 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $3.18 (-23.9%)
Spot @ $4.18

Negative ROIC of -35%, FCF of -$16.4M, and an Altman Z-Score of 0.2 signal forensic balance sheet risk.

Negative ROIC of -35%, FCF of -$16.4M, and an Altman Z-Score of 0.2 signal forensic balance sheet risk.. Look at the math on FOCL: paying current EV/EBITDA multiples for -35.0% ROIC and -35.0% operating margins leaves zero margin of safety if Biotechnology: Electromedical & Electrotherapeutic Apparatus demand softens. I'd wait for a retest of $3.68 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%